id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
961329_2 | Suxamethonium apnoea terminated with commercial serumcholinesterase. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"terminated\"]], \"start\": [[21]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Suxamethonium apnoea\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"commercial serumcholinesterase\"]], \"start\": [[37]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"commercial serumcholinesterase\"]], \"start\": [[37]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
9788533_1 | Fatal multiple drug intoxication following acute sertraline use. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[33]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"multiple drug intoxication\"]], \"start\": [[6]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"acute sertraline use\"]], \"start\": [[43]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"sertraline\"]], \"start\": [[49]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"Fatal\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
15611427_1 | OBSERVATIONS: We observed aggravation and spreading of a psoriatic plaque when treated topically with the toll-like receptor (TLR) 7 agonist imiquimod. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"observed\"]], \"start\": [[17]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"aggravation and spreading of a psoriatic plaque\"]], \"start\": [[26]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"the toll-like receptor (TLR) 7 agonist imiquimod\"]], \"start\": [[102]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"imiquimod\"]], \"start\": [[141]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"topically\"]], \"start\": [[87]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
9302445_2 | Hypercalcemia in an AIDS patient treated with growth hormone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[41]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Hypercalcemia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"an AIDS patient\"]], \"start\": [[17]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"growth hormone\"]], \"start\": [[46]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"AIDS\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"growth hormone\"]], \"start\": [[46]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
17383767_1 | Significant drug interaction: phenytoin toxicity due to erlotinib. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[49]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"phenytoin toxicity\"]], \"start\": [[30]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"erlotinib\"]], \"start\": [[56]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"erlotinib\"]], \"start\": [[56]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
10599932_2 | A pharmacokinetic interaction between the selective serotonin reuptake inhibitor citalopram and a tricyclic antidepressant, clomipramine, was noted in a patient treated for major depression and obsessive-compulsive disorder. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[18]], \"entity_id\": [\"T13\"]}, \"Effect\": {\"text\": [[\"A pharmacokinetic interaction\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"the selective serotonin reuptake inhibitor citalopram and a tricyclic antidepressant, clomipramine\"]], \"start\": [[38]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"citalopram\"], [\"clomipramine\"]], \"start\": [[81], [124]], \"entity_id\": [\"T16\", \"T17\"]}, \"Disorder\": {\"text\": [[\"depression\"], [\"obsessive-compulsive disorder\"]], \"start\": [[179], [194]], \"entity_id\": [\"T18\", \"T19\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[18]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"citalopram\"], [\"clomipramine\"]], \"start\": [[81], [124]], \"entity_id\": [\"T16\", \"T17\"]}}]}, \"Subject\": {\"text\": [[\"a patient treated for major depression and obsessive-compulsive disorder\"]], \"start\": [[151]], \"entity_id\": [\"T12\"]}}"
}
]
}
] |
3301251_4 | They continued to rise for five more days before salicylate hepatotoxicity was suspected. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"suspected\"]], \"start\": [[79]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"salicylate\"]], \"start\": [[49]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"salicylate\"]], \"start\": [[49]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hepatotoxicity\"]], \"start\": [[60]], \"entity_id\": [\"T4\"]}, \"Speculated\": {\"text\": [[\"suspected\"]], \"start\": [[79]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
8832451_2 | The occurrence of neuromuscular blockade and the resulting potentiation of muscle relaxants during magnesium sulfate (MgSO4) administration is well known. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[92]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"neuromuscular blockade\", \"potentiation of muscle relaxants\"]], \"start\": [[18, 59]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"magnesium sulfate\"]], \"start\": [[99]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"magnesium sulfate (MgSO4)\"]], \"start\": [[99]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
12680486_1 | Based on these findings, the patient was diagnosed with diabetes insipidus secondary to lithium therapy and was treated successfully with amiloride. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"diagnosed\"]], \"start\": [[41]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"diabetes insipidus\"]], \"start\": [[56]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"lithium\"]], \"start\": [[88]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"lithium\"]], \"start\": [[88]], \"entity_id\": [\"T7\"]}}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[112]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"successfully\"]], \"start\": [[120]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"amiloride\"]], \"start\": [[138]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"diabetes insipidus secondary to lithium therapy\"]], \"start\": [[56]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"amiloride\"]], \"start\": [[138]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
11034877_1 | Gabapentin-induced mood changes with hypomanic features in adults. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"adults\"]], \"start\": [[59]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"adults\"]], \"start\": [[59]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"mood changes with hypomanic features\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Gabapentin\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"Gabapentin\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
1954704_1 | Drug induced polymyositis secondary to leuprolide acetate (Lupron) therapy for prostate carcinoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary to\"]], \"start\": [[26]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"leuprolide acetate (Lupron) therapy\"]], \"start\": [[39]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"prostate carcinoma\"]], \"start\": [[79]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"leuprolide acetate (Lupron)\"]], \"start\": [[39]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"Drug induced polymyositis\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
18465737_1 | Incomplete posterior hyaloid detachment after intravitreal pegaptanib injection in diabetic macular edema. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[40]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Incomplete posterior hyaloid detachment\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"ntravitreal pegaptanib injection in diabetic macular edema\"]], \"start\": [[47]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"diabetic macular edema\"]], \"start\": [[83]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"pegaptanib\"]], \"start\": [[59]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"intravitreal\", \"injection\"]], \"start\": [[46, 70]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
7321956_2 | This paper reports a case of fatal perhexiline maleate liver injury. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"a case of\"]], \"start\": [[19]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"perhexiline maleate\"]], \"start\": [[35]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"perhexiline maleate\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"liver injury\"]], \"start\": [[55]], \"entity_id\": [\"T4\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[29]], \"entity_id\": [\"T7\"], \"value\": \"High\"}}"
}
]
}
] |
21448111_5 | During the second hospitalization it is possible that antipsychotic treatment combined with an antidepressant caused akathisia or there were symptoms of agitated depression and akathisia present at the same time, which is very difficult to determine in everyday clinical practice. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[110]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"antipsychotic treatment combined with an antidepressant\"]], \"start\": [[54]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"antipsychotic\"], [\"antidepressant\"]], \"start\": [[54], [95]], \"entity_id\": [\"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combined\"]], \"start\": [[78]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"antidepressant\"], [\"antipsychotic\"]], \"start\": [[95], [54]], \"entity_id\": [\"T13\", \"T12\"]}}]}, \"Effect\": {\"text\": [[\"akathisia\"]], \"start\": [[117]], \"entity_id\": [\"T9\"]}, \"Speculated\": {\"text\": [[\"possible\"]], \"start\": [[40]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
7724306_5 | OBJECTIVES: To describe the presentation and treatment of acute isoniazid (INH) neurotoxicity appearing at an inner-city municipal hospital. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"neurotoxicity\"]], \"start\": [[80]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"isoniazid (INH) neurotoxicity\"]], \"start\": [[64]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"isoniazid (INH)\"]], \"start\": [[64]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"isoniazid\"]], \"start\": [[64]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
9846036_4 | Clozapine, an atypical antipsychotic, can be toxic at doses 4 times a moderate dose. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"be\"]], \"start\": [[42]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"doses 4 times a moderate dose\", \"Clozapine\"]], \"start\": [[54, 0]], \"entity_id\": [\"T6\"], \"Dosage\": {\"text\": [[\"4 times a moderate dose\"]], \"start\": [[60]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"Clozapine\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"toxic\"]], \"start\": [[45]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
18344455_3 | This article presents a 3(1/2)-year-old child on valproic acid, lamotrigine, and phenytoin who developed simultaneous hepatotoxicity and bone marrow toxicity during a parainfluenza virus type 3 infection. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[95]], \"entity_id\": [\"T13\"]}, \"Subject\": {\"text\": [[\"a 3(1/2)-year-old child\"]], \"start\": [[22]], \"entity_id\": [\"T11\"], \"Age\": {\"text\": [[\"3(1/2)-year-old\"], [\"child\"]], \"start\": [[24], [40]], \"entity_id\": [\"T15\", \"T16\"]}}, \"Treatment\": {\"text\": [[\"valproic acid, lamotrigine, and phenytoin\"]], \"start\": [[49]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"valproic acid\"], [\"lamotrigine\"], [\"phenytoin\"]], \"start\": [[49], [64], [81]], \"entity_id\": [\"T17\", \"T18\", \"T20\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[77]], \"entity_id\": [\"T19\"]}, \"Drug\": {\"text\": [[\"phenytoin\"], [\"lamotrigine\"], [\"valproic acid\"]], \"start\": [[81], [64], [49]], \"entity_id\": [\"T20\", \"T18\", \"T17\"]}}]}, \"Effect\": {\"text\": [[\"simultaneous hepatotoxicity and bone marrow toxicity\"]], \"start\": [[105]], \"entity_id\": [\"T14\"]}}"
}
]
}
] |
2051906_3 | Reversible cholestasis with bile duct injury following azathioprine therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[45]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Reversible cholestasis with bile duct injury\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"azathioprine\"]], \"start\": [[55]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"azathioprine\"]], \"start\": [[55]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
20185472_1 | The authors report five cases of tremor related to itraconazole therapy, which occurred within 1-12 months of initiating treatment and resolved gradually following itraconazole withdrawal. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[40]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"tremor\"]], \"start\": [[33]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"itraconazole therapy,\"]], \"start\": [[51]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"itraconazole\"]], \"start\": [[51]], \"entity_id\": [\"T7\"]}, \"Time_elapsed\": {\"text\": [[\"within 1-12 months\"]], \"start\": [[88]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
9337441_2 | OBJECTIVE: To report a case of phenolphthalein-induced toxic epidermal necrolysis (TEN) in a patient maintained on several other medications more commonly known to be associated with TEN. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[47]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"toxic epidermal necrolysis (TEN)\"]], \"start\": [[55]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a case of\", \"a patient\"]], \"start\": [[21, 91]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"phenolphthalein\", \"maintained on several other medications more commonly known to be associated with TEN\"]], \"start\": [[31, 101]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"phenolphthalein\"]], \"start\": [[31]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
1295628_3 | Clinical symptoms and leukopenia normalized after discontinuation of CBZ and administration of prednisolone at 40 mg. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"normalized\"]], \"start\": [[33]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Clinical symptoms and leukopenia normalized\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"discontinuation of CBZ and administration of prednisolone at 40 mg\"]], \"start\": [[50]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"CBZ\"], [\"prednisolone\"]], \"start\": [[69], [95]], \"entity_id\": [\"T11\", \"T12\"]}, \"Dosage\": {\"text\": [[\"40 mg\"]], \"start\": [[111]], \"entity_id\": [\"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[73]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"CBZ\"], [\"prednisolone\"]], \"start\": [[69], [95]], \"entity_id\": [\"T11\", \"T12\"]}}]}}"
}
]
}
] |
6766717_1 | A patient with alcoholic cerebellar degeneration had periodic alternating nystagmus during a period of phenytoin intoxication. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[84]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"A patient with alcoholic cerebellar degeneration\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"alcoholic cerebellar degeneration\"]], \"start\": [[15]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"phenytoin\"]], \"start\": [[103]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"phenytoin\"]], \"start\": [[103]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"periodic alternating nystagmus\"]], \"start\": [[53]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
15316423_1 | Extensive forearm deep venous thrombosis following a severe infliximab infusion reaction. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[41]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Extensive forearm deep venous thrombosis\"], [\"nfusion reaction\"]], \"start\": [[0], [72]], \"entity_id\": [\"T3\", \"T6\"]}, \"Treatment\": {\"text\": [[\"infliximab\"]], \"start\": [[60]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"infliximab\"]], \"start\": [[60]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[53]], \"entity_id\": [\"T7\"], \"value\": \"Medium\"}}"
}
]
}
] |
527355_2 | Severe acidosis from acetazolamide in a diabetic patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"from\"]], \"start\": [[16]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a diabetic patient\"]], \"start\": [[38]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"diabetic\"]], \"start\": [[40]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Severe acidosis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"acetazolamide\"]], \"start\": [[21]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"acetazolamide\"]], \"start\": [[21]], \"entity_id\": [\"T9\"]}}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"value\": \"Medium\"}}"
}
]
}
] |
18607107_1 | CONCLUSIONS: Clinicians should be aware that Crohn's disease is a potential novel adverse drug effect of Copaxone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"effect\"]], \"start\": [[95]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Crohn's disease\"]], \"start\": [[45]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Copaxone\"]], \"start\": [[105]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Copaxone\"]], \"start\": [[105]], \"entity_id\": [\"T7\"]}}, \"Speculated\": {\"text\": [[\"potential\"]], \"start\": [[66]], \"entity_id\": [\"T5\"], \"value\": true}}"
}
]
}
] |
16062101_2 | ADR induced by drug treatment can be a side effect of treatment with antipsychotic drugs and other drugs; however, there have been no reports of lamivudine-induced ADR in the English literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[156]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"lamivudine\"]], \"start\": [[145]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"lamivudine\"]], \"start\": [[145]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"ADR\"]], \"start\": [[164]], \"entity_id\": [\"T6\"]}, \"Negated\": {\"text\": [[\"no\"]], \"start\": [[131]], \"entity_id\": [\"T3\"], \"value\": true}}"
}
]
}
] |
17324248_2 | CONCLUSIONS: The piloerection observed after the replacement of fluvoxamine with milnacipran in this patient appears to have been due to an increase in the alpha(1)-adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[217]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"milnacipran\"]], \"start\": [[228]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"milnacipran\"]], \"start\": [[228]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"an increase in the alpha(1)-adrenoceptor occupancy by endogenous norepinephrine\"]], \"start\": [[137]], \"entity_id\": [\"T7\"]}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"observed\"]], \"start\": [[30]], \"entity_id\": [\"T13\"]}, \"Effect\": {\"text\": [[\"piloerection\"]], \"start\": [[17]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"this patient\"]], \"start\": [[96]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"milnacipran\"]], \"start\": [[81]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"milnacipran\"]], \"start\": [[81]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
17122225_1 | Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"from\"]], \"start\": [[19]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Serotonin syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"interaction of cyclobenzaprine with other serotoninergic drugs\"]], \"start\": [[28]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"cyclobenzaprine\"], [\"serotoninergic drugs\"]], \"start\": [[43], [70]], \"entity_id\": [\"T9\", \"T10\"]}}}"
}
]
}
] |
19897274_1 | However, a recent post-marketing survey in Japan revealed that interstitial pneumonia occurred in 4 among approximately 2 000 Japanese patients treated with sorafenib. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[86]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"4 among approximately 2 000 Japanese patients\"]], \"start\": [[98]], \"entity_id\": [\"T3\"], \"Race\": {\"text\": [[\"Japanese\"]], \"start\": [[126]], \"entity_id\": [\"T8\"]}, \"Population\": {\"text\": [[\"4 among approximately 2 000\"]], \"start\": [[98]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"sorafenib\"]], \"start\": [[157]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"sorafenib\"]], \"start\": [[157]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"interstitial pneumonia\"]], \"start\": [[63]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
20338114_2 | The other patient developed transient intraoperative hypertension immediately after inadvertent submucosal injection of concentrated epinephrine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[18]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"transient intraoperative hypertension immediately\"]], \"start\": [[28]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"inadvertent submucosal injection of concentrated epinephrine\"]], \"start\": [[84]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"epinephrine\"]], \"start\": [[133]], \"entity_id\": [\"T5\"]}, \"Route\": {\"text\": [[\"injection\"]], \"start\": [[107]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"The other patient\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
1722991_9 | This experience supports the hypothesis that heparin can be readministered early to patients with heparin-associated thrombocytopenia and thrombosis, provided antiplatelet therapy is given. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"readministered\"]], \"start\": [[60]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"heparin\", \"antiplatelet therapy is given\"]], \"start\": [[45, 159]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"heparin-associated thrombocytopenia\"]], \"start\": [[98]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"heparin\"], [\"antiplatelet\"]], \"start\": [[45], [159]], \"entity_id\": [\"T14\", \"T18\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"given\"]], \"start\": [[183]], \"entity_id\": [\"T19\"]}, \"Drug\": {\"text\": [[\"antiplatelet\"], [\"heparin\"]], \"start\": [[159], [45]], \"entity_id\": [\"T18\", \"T14\"]}}]}, \"Speculated\": {\"text\": [[\"hypothesis\"]], \"start\": [[29]], \"entity_id\": [\"T20\"], \"value\": true}}"
},
{
"event_id": "E3",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E3\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[106]], \"entity_id\": [\"T21\"]}, \"Treatment\": {\"text\": [[\"heparin\"]], \"start\": [[98]], \"entity_id\": [\"T24\"], \"Drug\": {\"text\": [[\"heparin\"]], \"start\": [[98]], \"entity_id\": [\"T22\"]}}, \"Effect\": {\"text\": [[\"thrombocytopenia and thrombosis\"]], \"start\": [[117]], \"entity_id\": [\"T23\"]}}"
}
]
}
] |
3997294_1 | Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[65]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Pneumonitis with pleural and pericardial effusion and neuropathy\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"amiodarone therapy\"]], \"start\": [[72]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[72]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
15852680_2 | We report a case of interstitial pneumonitis induced by bicalutamide and/or leuprorelin acetate given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[45]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"interstitial pneumonitis\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[10]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"bicalutamide and/or leuprorelin acetate given as therapy for prostate cancer\"]], \"start\": [[56]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"prostate cancer\"]], \"start\": [[117]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"bicalutamide\"], [\"leuprorelin acetate\"]], \"start\": [[56], [76]], \"entity_id\": [\"T9\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[69]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"bicalutamide\"], [\"leuprorelin acetate\"]], \"start\": [[56], [76]], \"entity_id\": [\"T9\", \"T11\"]}}]}}"
}
]
}
] |
10410183_9 | For those patients with a history of NMS, or even of isolated serum CK elevation during antipsychotic therapy, follow-up should be stricter. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[81]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"patients with a history of NMS\"]], \"start\": [[10]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"a history of NMS\"]], \"start\": [[24]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"isolated serum CK elevation\"]], \"start\": [[53]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"antipsychotic therapy\"]], \"start\": [[88]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
8292513_2 | Children with acute lymphoblastic leukemia (ALL), treated with L-asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"risk\"]], \"start\": [[85]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"L-asparaginase\"]], \"start\": [[63]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"L-asparaginase\"]], \"start\": [[63]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"acute lymphoblastic leukemia (ALL)\"]], \"start\": [[14]], \"entity_id\": [\"T14\"]}}, \"Subject\": {\"text\": [[\"Children with acute lymphoblastic leukemia (ALL)\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"Children\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"cerebral thrombosis or hemorrhage\", \"coagulation protein deficiencies\"]], \"start\": [[94, 139]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
8530331_6 | Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment; the encephalopathy resolved when the patients were switched to clozapine treatment. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[55]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"Two of the five patients who worsened motorically\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"Two of the five\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"worsened motorically\"]], \"start\": [[29]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"encephalopathy\"]], \"start\": [[65]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"risperidone treatment\"]], \"start\": [[87]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"risperidone\"]], \"start\": [[87]], \"entity_id\": [\"T14\"]}}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"resolved\"]], \"start\": [[129]], \"entity_id\": [\"T1\"]}, \"Subject\": {\"text\": [[\"Two of the five patients who worsened motorically\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"Two of the five\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"worsened motorically\"]], \"start\": [[29]], \"entity_id\": [\"T13\"]}}, \"Treatment\": {\"text\": [[\"switched to clozapine treatment\"]], \"start\": [[161]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"encephalopathy\"]], \"start\": [[114]], \"entity_id\": [\"T2\"]}, \"Drug\": {\"text\": [[\"clozapine\"]], \"start\": [[173]], \"entity_id\": [\"T4\"]}}}"
}
]
}
] |
25157214_2 | The effectiveness of sugammadex in reversing rocuronium-induced neuromuscular blockade (NMB) in the presence of drugs that may potentiate NMB remains to be fully established. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[56]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"rocuronium\"]], \"start\": [[45]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"rocuronium\"]], \"start\": [[45]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"neuromuscular blockade (NMB)\"]], \"start\": [[64]], \"entity_id\": [\"T10\"]}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"reversing\"]], \"start\": [[35]], \"entity_id\": [\"T15\"]}, \"Treatment\": {\"text\": [[\"sugammadex\", \"in the presence of drugs that may potentiate NMB\"]], \"start\": [[21, 93]], \"entity_id\": [\"T13\"], \"Disorder\": {\"text\": [[\"rocuronium-induced neuromuscular blockade (NMB)\"]], \"start\": [[45]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"sugammadex\"]], \"start\": [[21]], \"entity_id\": [\"T14\"]}}, \"Speculated\": {\"text\": [[\"remains to be fully established\"]], \"start\": [[142]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
2781955_1 | Dexamethasone treatment of amiodarone-induced thyrotoxicosis (AIT) with or without persistent administration of the drug. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[38]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"amiodarone\"]], \"start\": [[27]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[27]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"thyrotoxicosis (AIT)\"]], \"start\": [[46]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
7973922_1 | Acyclovir neurotoxicity: clinical experience and review of the literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"experience\"]], \"start\": [[34]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Acyclovir\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Acyclovir\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"neurotoxicity\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
24163322_1 | Inadvertent exaggerated anticoagulation following use of bismuth subsalicylate in an enterally fed patient receiving warfarin therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[40]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Inadvertent exaggerated anticoagulation\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"bismuth subsalicylate\", \"warfarin therapy\"]], \"start\": [[57, 117]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"warfarin\"], [\"bismuth subsalicylate\"]], \"start\": [[117], [57]], \"entity_id\": [\"T11\", \"T12\"]}}, \"Subject\": {\"text\": [[\"an enterally fed patient\"]], \"start\": [[82]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
9230324_1 | We report the specifics of 12 cases of severe hypertension after the intraoperative use of topical phenylephrine, submucosal epinephrine, or both. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[59]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"12 cases\"]], \"start\": [[27]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"12\"]], \"start\": [[27]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"intraoperative use of topical phenylephrine, submucosal epinephrine, or both\"]], \"start\": [[69]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"phenylephrine\"], [\"epinephrine\"]], \"start\": [[99], [125]], \"entity_id\": [\"T9\", \"T10\"]}, \"Route\": {\"text\": [[\"topical\"], [\"submucosal\"]], \"start\": [[91], [114]], \"entity_id\": [\"T11\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"or both\"]], \"start\": [[138]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"epinephrine\"], [\"phenylephrine\"]], \"start\": [[125], [99]], \"entity_id\": [\"T10\", \"T9\"]}}]}, \"Effect\": {\"text\": [[\"hypertension\"]], \"start\": [[46]], \"entity_id\": [\"T7\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[39]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
8384030_5 | The patient experienced muscle twitches, tremulousness, and anxiety on day 17 of foscarnet therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"experienced\"]], \"start\": [[12]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"muscle twitches, tremulousness, and anxiet\"]], \"start\": [[24]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"foscarnet therapy\"]], \"start\": [[81]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"foscarnet\"]], \"start\": [[81]], \"entity_id\": [\"T11\"]}, \"Time_elapsed\": {\"text\": [[\"on day 17\"]], \"start\": [[68]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[4]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
7282702_1 | A case of timolol-associated heart failure in a 73-year old white man is reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a 73-year old white man\"]], \"start\": [[46]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"73-year old\"]], \"start\": [[48]], \"entity_id\": [\"T7\"]}, \"Race\": {\"text\": [[\"white\"]], \"start\": [[60]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[66]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"timolol\"]], \"start\": [[10]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"timolol\"]], \"start\": [[10]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"heart failure\"]], \"start\": [[29]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
25407257_6 | In December, he was prescribed 160 mg/day tebipenem pivoxil by an otolaryngologist for inflammation of the tympanic membrane. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"for\"]], \"start\": [[83]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"160 mg/day tebipenem pivoxil\"]], \"start\": [[31]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"inflammation of the tympanic membrane\"]], \"start\": [[87]], \"entity_id\": [\"T6\"]}, \"Dosage\": {\"text\": [[\"160 mg/day\"]], \"start\": [[31]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"tebipenem pivoxil\"]], \"start\": [[42]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"he\"]], \"start\": [[13]], \"entity_id\": [\"T8\"], \"Gender\": {\"text\": [[\"he\"]], \"start\": [[13]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
19669617_1 | A 65-year-old female patient presented with jaundice followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of adalimumab. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[29]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"1 week after the fourth dose of adalimumab\"]], \"start\": [[151]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"adalimumab\"]], \"start\": [[183]], \"entity_id\": [\"T13\"]}, \"Time_elapsed\": {\"text\": [[\"1 week after\"]], \"start\": [[151]], \"entity_id\": [\"T14\"]}, \"Dosage\": {\"text\": [[\"fourth dose\"]], \"start\": [[168]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"jaundice followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat\"]], \"start\": [[44]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"A 65-year-old female patient\"]], \"start\": [[0]], \"entity_id\": [\"T10\"], \"Age\": {\"text\": [[\"65-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T11\"]}, \"Gender\": {\"text\": [[\"female\"]], \"start\": [[14]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
4082283_2 | Renal failure is a rare complication associated with the use of rifampicin for the treatment of tuberculosis, usually occurring well into the course of therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[37]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Renal failure\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"rifampicin\"]], \"start\": [[64]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"rifampicin\"]], \"start\": [[64]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"tuberculosis\"]], \"start\": [[96]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
21887897_1 | An autopsy case of multiple psychotropic drug poisoning. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"poisoning\"]], \"start\": [[46]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"poisoning\"]], \"start\": [[46]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"multiple psychotropic drug\"]], \"start\": [[19]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"psychotropic\"]], \"start\": [[28]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"An autopsy case\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
2212262_1 | Severe heparin associated thrombocytopenia is a rare complication of heparin therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[15]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"heparin\"]], \"start\": [[7]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"heparin\"]], \"start\": [[7]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"thrombocytopenia\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"value\": \"High\"}}"
}
]
}
] |
10546851_5 | Six patients at steady state in treatment with indinavir participated in the study. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"Six patients\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"Six\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"indinavir\"]], \"start\": [[47]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"indinavir\"]], \"start\": [[47]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
19034138_6 | RESULTS: A 52-year-old woman with Parkinson disease who had taken amantadine for 6 years had bilateral corneal edema for 2 months at baseline. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"had\"]], \"start\": [[89]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A 52-year-old woman with Parkinson disease\"]], \"start\": [[9]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"52-year-old\"]], \"start\": [[11]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[23]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"bilateral corneal edema for 2 months at baseline\"]], \"start\": [[93]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"taken amantadine for 6 years\"]], \"start\": [[60]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"Parkinson disease\"]], \"start\": [[34]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"amantadine\"]], \"start\": [[66]], \"entity_id\": [\"T10\"]}, \"Duration\": {\"text\": [[\"6 years\"]], \"start\": [[81]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
12114387_3 | We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[157]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"2 months of treatment with epoprostenol\"]], \"start\": [[116]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"epoprostenol\"]], \"start\": [[143]], \"entity_id\": [\"T17\"]}, \"Time_elapsed\": {\"text\": [[\"after 2 months\"]], \"start\": [[110]], \"entity_id\": [\"T18\"]}, \"Disorder\": {\"text\": [[\"pulmonary hypertension\"], [\"undifferentiated connective tissue disease\"]], \"start\": [[35], [62]], \"entity_id\": [\"T19\", \"T20\"]}}, \"Effect\": {\"text\": [[\"rapidly progressive erythema, scaling, nausea and vomiting, and fever\"]], \"start\": [[172]], \"entity_id\": [\"T13\"]}, \"Subject\": {\"text\": [[\"a patient with pulmonary hypertension and undifferentiated connective tissue disease\"]], \"start\": [[20]], \"entity_id\": [\"T14\"]}}"
}
]
}
] |
12587815_3 | Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[48]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Neuroleptic malignant syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"olanzapine-lithium combination therapy\"]], \"start\": [[58]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"olanzapine\"], [\"lithium\"]], \"start\": [[58], [69]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[77]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"lithium\"], [\"olanzapine\"]], \"start\": [[69], [58]], \"entity_id\": [\"T10\", \"T9\"]}}]}, \"Subject\": {\"text\": [[\"adolescent\"]], \"start\": [[37]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
3878320_1 | A lethal complication of peripheral vein vasopressin infusion. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[9]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"complication\"]], \"start\": [[9]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"peripheral vein vasopressin infusion\"]], \"start\": [[25]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"peripheral vein\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"vasopressin\"]], \"start\": [[41]], \"entity_id\": [\"T7\"]}}, \"Severity\": {\"text\": [[\"lethal\"]], \"start\": [[2]], \"entity_id\": [\"T8\"], \"value\": \"High\"}}"
}
]
}
] |
16641839_3 | Cutaneous eruptions occur in 3% of individuals administered carbamazepine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occur\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Cutaneous eruptions\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"carbamazepine\"]], \"start\": [[60]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"carbamazepine\"]], \"start\": [[60]], \"entity_id\": [\"T6\"]}}, \"Speculated\": {\"text\": [[\"3% of individuals\"]], \"start\": [[29]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
23868369_2 | A 27 year old female with a complex history of congenital heart disease, cardiac surgery, heart failure, and arrhythmias was admitted for a Pseudomonas aeruginosa sternal wound infection and treated with intravenous antibiotics. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[191]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"A 27 year old female with a complex history of congenital heart disease, cardiac surgery, heart failure, and arrhythmias\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"27 year old\"]], \"start\": [[2]], \"entity_id\": [\"T12\"]}, \"Gender\": {\"text\": [[\"female\"]], \"start\": [[14]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"congenital heart disease\"], [\"cardiac surgery\"], [\"heart failure\"], [\"arrhythmias\"]], \"start\": [[47], [73], [90], [109]], \"entity_id\": [\"T14\", \"T15\", \"T16\", \"T17\"]}}, \"Treatment\": {\"text\": [[\"intravenous antibiotics\"]], \"start\": [[204]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"antibiotics\"]], \"start\": [[216]], \"entity_id\": [\"T18\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[204]], \"entity_id\": [\"T19\"]}, \"Disorder\": {\"text\": [[\"a Pseudomonas aeruginosa sternal wound infection\"]], \"start\": [[138]], \"entity_id\": [\"T20\"]}}}"
}
]
}
] |
8244201_2 | Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole-trimethoprim (co-trimoxazole) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"described\"]], \"start\": [[114]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"oral therapy of sulfamethoxazole-trimethoprim (co-trimoxazole)\"]], \"start\": [[48]], \"entity_id\": [\"T8\"], \"Route\": {\"text\": [[\"oral\"]], \"start\": [[48]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"sulfamethoxazole-trimethoprim\"]], \"start\": [[64]], \"entity_id\": [\"T16\"]}, \"Disorder\": {\"text\": [[\"Pneumocystis carinii pneumonia\"]], \"start\": [[195]], \"entity_id\": [\"T1\"]}}, \"Subject\": {\"text\": [[\"2 elderly Japanese patients with lymphoid malignancy\"]], \"start\": [[127]], \"entity_id\": [\"T9\"], \"Population\": {\"text\": [[\"2\"]], \"start\": [[127]], \"entity_id\": [\"T11\"]}, \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[129]], \"entity_id\": [\"T12\"]}, \"Race\": {\"text\": [[\"Japanese\"]], \"start\": [[137]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"lymphoid malignancy\"]], \"start\": [[160]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"Hyperkalaemia with renal tubular dysfunction\"]], \"start\": [[0]], \"entity_id\": [\"T2\"]}}"
}
]
}
] |
18067642_4 | This is the first report on the histopathological findings of thyroid tissue from a patient with amiodarone-induced hypothyroidism. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[108]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"hypothyroidism\"]], \"start\": [[116]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"amiodarone\"]], \"start\": [[97]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[97]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
8771575_2 | Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life-threatening pulmonary dysfunction. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"are\"]], \"start\": [[44]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Acute pulmonary reactions\", \"can cause minor or life-threatening pulmonary dysfunction\"]], \"start\": [[0, 87]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"nitrofurantoin\"]], \"start\": [[29]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"nitrofurantoin\"]], \"start\": [[29]], \"entity_id\": [\"T10\"]}}, \"Speculated\": {\"text\": [[\"can\"]], \"start\": [[87]], \"entity_id\": [\"T8\"], \"value\": true}, \"Severity\": {\"text\": [[\"minor or life-threatening\"]], \"start\": [[97]], \"entity_id\": [\"T9\"], \"value\": \"Medium\"}}"
}
]
}
] |
2554727_2 | High-dose cytosine arabinoside may benefit patients with refractory acute leukemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"benefit\"]], \"start\": [[35]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"High-dose cytosine arabinoside\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"refractory acute leukemia\"]], \"start\": [[57]], \"entity_id\": [\"T9\"]}, \"Dosage\": {\"text\": [[\"High-dose\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"cytosine arabinoside\"]], \"start\": [[10]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"patients with refractory acute leukemia\"]], \"start\": [[43]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[31]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
2452936_1 | Life-threatening hyponatremia caused by vinblastine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[30]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"hyponatremia\"]], \"start\": [[17]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"vinblastine\"]], \"start\": [[40]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"vinblastine\"]], \"start\": [[40]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
17556909_3 | We report a myeloma patient who developed severe paralytic ileus during bortezomib therapy, which presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation, suggesting a direct causal relationship. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a myeloma patient\"]], \"start\": [[10]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"paralytic ileus\", \"presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation\"]], \"start\": [[49, 98]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"bortezomib therapy\"]], \"start\": [[72]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"myeloma\"]], \"start\": [[12]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"bortezomib\"]], \"start\": [[72]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[42]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
12776809_4 | Here, we report on the drug safety of coumarin with special respect to liver reaction. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"respect\"]], \"start\": [[60]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"coumarin\"]], \"start\": [[38]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"coumarin\"]], \"start\": [[38]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"liver reaction\"]], \"start\": [[71]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"report\"]], \"start\": [[9]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
7865488_2 | However, EO-induced noncardiogenic pulmonary edema has not been reported in human. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"EO\"]], \"start\": [[9]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"EO\"]], \"start\": [[9]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"noncardiogenic pulmonary edema\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"human\"]], \"start\": [[76]], \"entity_id\": [\"T7\"]}, \"Negated\": {\"text\": [[\"not\"]], \"start\": [[55]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
12944250_2 | Since the thrombocyte count started to increase immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and tazobactam/piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"Since\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"discontinuation of ciprofloxacin and tazobactam/piperacillin\"]], \"start\": [[107]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ciprofloxacin\"], [\"tazobactam/piperacillin\"]], \"start\": [[126], [144]], \"entity_id\": [\"T8\", \"T9\"]}, \"Dosage\": {\"text\": [[\"discontinuation\"]], \"start\": [[107]], \"entity_id\": [\"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[140]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"tazobactam/piperacillin\"], [\"ciprofloxacin\"]], \"start\": [[144], [126]], \"entity_id\": [\"T9\", \"T8\"]}}]}, \"Effect\": {\"text\": [[\"the thrombocyte count started to increase immediately after initiation and dropped immediately\"]], \"start\": [[6]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
8586895_1 | However, in 1993, a clinical study involving 400 patients on the Thai-Burmese border revealed cardiac effects of antimalarial treatment with halofantrine, including one sudden death after the treatment. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"effects\"]], \"start\": [[102]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"halofantrine\"]], \"start\": [[141]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"halofantrine\"], [\"antimalarial treatment\"]], \"start\": [[141], [113]], \"entity_id\": [\"T11\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[136]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"halofantrine\"], [\"antimalarial treatment\"]], \"start\": [[141], [113]], \"entity_id\": [\"T11\", \"T13\"]}}]}, \"Subject\": {\"text\": [[\"400 patients on the Thai-Burmese border\"]], \"start\": [[45]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"400\"]], \"start\": [[45]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"cardiac effects\", \"sudden death\"]], \"start\": [[94, 169]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
10723699_1 | Tetracycline-induced benign intracranial hypertension. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[13]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Tetracycline\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"a\"]], \"start\": [[4]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"benign intracranial hypertension\"]], \"start\": [[21]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
12889716_2 | Only one case of a generalized maculopapular rash with enoxaparin has been reported in Europe. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[50]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"one case\"]], \"start\": [[5]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"one\"]], \"start\": [[5]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"generalized maculopapular rash\"]], \"start\": [[19]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"enoxaparin\"]], \"start\": [[55]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"enoxaparin\"]], \"start\": [[55]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
15331204_7 | After 3- to 13-month period of therapy without indapamide, glucose levels of all patients decreased and diabetes disappeared. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"After\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"3- to 13-month period of therapy without indapamide\"]], \"start\": [[6]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"indapamide\"]], \"start\": [[47]], \"entity_id\": [\"T6\"]}, \"Time_elapsed\": {\"text\": [[\"3- to 13-month\"]], \"start\": [[6]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"glucose levels of all patients decreased and diabetes disappeared\"]], \"start\": [[59]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
10679548_4 | The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of nitrofurantoin induced BOOP. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[128]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"nitrofurantoin\"]], \"start\": [[113]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"nitrofurantoin\"]], \"start\": [[113]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"BOOP\"]], \"start\": [[136]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"two patients\"]], \"start\": [[32]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[32]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
12163813_3 | Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"extravasation\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"vasopressin\"]], \"start\": [[46]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"vasopressin\"]], \"start\": [[46]], \"entity_id\": [\"T6\"]}, \"Disorder\": {\"text\": [[\"septic shock\"]], \"start\": [[75]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Skin necrosis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
24477376_4 | The patient was previously on phenytoin and was initiated on ticagrelor for antiplatelet therapy following stent placement. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"for\"]], \"start\": [[72]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"The patient\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"previously on phenytoin\", \"initiated on ticagrelor\", \"following stent placement\"]], \"start\": [[16, 48, 97]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"antiplatelet therapy\"]], \"start\": [[76]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"phenytoin\"], [\"ticagrelor\"]], \"start\": [[30], [61]], \"entity_id\": [\"T10\", \"T11\"]}}}"
}
]
}
] |
8239963_1 | Clonidine-induced bradycardia in patients with spinal cord injury. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Clonidine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"spinal cord injury\"]], \"start\": [[47]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"Clonidine\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"bradycardia\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patients with spinal cord injury\"]], \"start\": [[33]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
11122162_1 | MI related to the use of activated and non-activated PCCs predominantly affects young patients who often have no preceding history of, or risk factors for, MI and tends to be associated with large cumulative doses of concentrate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[3]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"MI\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"activated and non-activated PCCs\", \"large cumulative doses of concentrate\"]], \"start\": [[25, 191]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"non-activated PCCs\"], [\"activated\", \"PCCs\"]], \"start\": [[39], [25, 53]], \"entity_id\": [\"T8\", \"T10\"]}, \"Dosage\": {\"text\": [[\"large cumulative doses\"]], \"start\": [[191]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"young patients who often have no preceding history of, or risk factors for, MI\"]], \"start\": [[80]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"young\"]], \"start\": [[80]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
6093724_3 | To our knowledge, we describe the first reported case of isolated paresthesia and peripheral neuropathy, without systemic involvement, secondary to sulindac administration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary\"]], \"start\": [[135]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"isolated paresthesia and peripheral neuropathy\"]], \"start\": [[57]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"sulindac administration\"]], \"start\": [[148]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"sulindac\"]], \"start\": [[148]], \"entity_id\": [\"T9\"]}}, \"Speculated\": {\"text\": [[\"To our knowledge\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
9876809_2 | To report a probable case of ticlopidine-induced phenytoin toxicity. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[41]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"phenytoin\", \"ticlopidine\"]], \"start\": [[49, 29]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ticlopidine\"], [\"phenytoin\"]], \"start\": [[29], [49]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[41]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"ticlopidine\"], [\"phenytoin\"]], \"start\": [[29], [49]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Subject\": {\"text\": [[\"a probable case\"]], \"start\": [[10]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"phenytoin toxicity\"]], \"start\": [[49]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"probable\"]], \"start\": [[12]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
3558331_2 | Two patients are described in whom subtle cognitive impairments are associated with therapeutic doses of amoxapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[68]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"therapeutic doses of amoxapine\"]], \"start\": [[84]], \"entity_id\": [\"T4\"], \"Dosage\": {\"text\": [[\"therapeutic doses\"]], \"start\": [[84]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"amoxapine\"]], \"start\": [[105]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"subtle cognitive impairments\"]], \"start\": [[35]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"Two patients\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Severity\": {\"text\": [[\"subtle\"]], \"start\": [[35]], \"entity_id\": [\"T10\"], \"value\": \"Low\"}}"
}
]
}
] |
16012330_2 | Itraconazole is particularly attractive in fungal prophylaxis for cancer patients due to its broad spectrum, including Candida and Aspergillus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"prophylaxis\"]], \"start\": [[50]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Itraconazole\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"fungal\"]], \"start\": [[43]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"Itraconazole\"]], \"start\": [[0]], \"entity_id\": [\"T15\"]}}, \"Subject\": {\"text\": [[\"cancer patients\"]], \"start\": [[66]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"cancer\"]], \"start\": [[66]], \"entity_id\": [\"T13\"]}}, \"Speculated\": {\"text\": [[\"attractive\"]], \"start\": [[29]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
16062101_4 | The authors think that although lamivudine is widely used and well tolerated, it can cause ADRs, which are reversible after drug withdrawal. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[85]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"ADRs\"]], \"start\": [[91]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"lamivudine\"]], \"start\": [[32]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"lamivudine\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
1751354_1 | Psoriasis induced by interferon-alpha. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Psoriasis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"interferon-alpha\"]], \"start\": [[21]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"interferon-alpha\"]], \"start\": [[21]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
12915840_2 | We report the first case of IHA associated with cefuroxime administration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[32]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"IHA\"]], \"start\": [[28]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"cefuroxime\"]], \"start\": [[48]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"cefuroxime\"]], \"start\": [[48]], \"entity_id\": [\"T6\"]}}, \"Subject\": {\"text\": [[\"the first case\"]], \"start\": [[10]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
7577414_3 | We report a 16-year-old male who developed nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus after treatment with griseofulvin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[170]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a 16-year-old male\"]], \"start\": [[10]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"16-year-old\"]], \"start\": [[12]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[24]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"treatment with griseofulvin\"]], \"start\": [[176]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"griseofulvin\"]], \"start\": [[191]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus\"]], \"start\": [[43]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
10803790_5 | CONCLUSION: In some abstainers who take cyanamide for several years, thin septum-like liver fibrosis progresses along with the emergence of ground-glass hepatocytes. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"In\"]], \"start\": [[12]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"some abstainers\"]], \"start\": [[15]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"take cyanamide for several years\"]], \"start\": [[35]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"cyanamide\"]], \"start\": [[40]], \"entity_id\": [\"T9\"]}, \"Freq\": {\"text\": [[\"several years\"]], \"start\": [[54]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"thin septum-like liver fibrosis progresses along with the emergence of ground-glass hepatocytes\"]], \"start\": [[69]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
1814986_1 | Metabolic acidosis induced by acetazolamide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[19]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"acetazolamide\"]], \"start\": [[30]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"acetazolamide\"]], \"start\": [[30]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Metabolic acidosis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
15359206_2 | In this paper we report a case of nimodipine overdosage resulting in prolonged hypotension and hypoxemia, which was successfully treated with calcium gluconate. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulting\"]], \"start\": [[56]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"nimodipine overdosage\"]], \"start\": [[34]], \"entity_id\": [\"T6\"], \"Dosage\": {\"text\": [[\"overdosage\"]], \"start\": [[45]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"nimodipine\"]], \"start\": [[34]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"prolonged hypotension and hypoxemia\"]], \"start\": [[69]], \"entity_id\": [\"T7\"]}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[129]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"calcium gluconate\"]], \"start\": [[142]], \"entity_id\": [\"T13\"], \"Disorder\": {\"text\": [[\"prolonged hypotension and hypoxemia\"]], \"start\": [[69]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"calcium gluconate\"]], \"start\": [[142]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
21512888_4 | Valproic acid also displaces warfarin from the protein binding sites resulting in significant INR changes but this type of drug interaction is less well known. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulting\"]], \"start\": [[69]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Valproic acid also displaces warfarin from the protein binding sites\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Valproic acid\"], [\"warfarin\"]], \"start\": [[0], [29]], \"entity_id\": [\"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"displaces\"]], \"start\": [[19]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"Valproic acid\"], [\"warfarin\"]], \"start\": [[0], [29]], \"entity_id\": [\"T12\", \"T13\"]}}]}, \"Effect\": {\"text\": [[\"significant INR changes\"]], \"start\": [[82]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"less well known\"]], \"start\": [[143]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
15190230_3 | Therapy with IFN-alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and depressive disorders. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated with\"]], \"start\": [[30]], \"entity_id\": [\"T12\"]}, \"Effect\": {\"text\": [[\"neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and depressive disorders\"]], \"start\": [[58]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"Therapy with IFN-alpha\"]], \"start\": [[0]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"IFN-alpha\"]], \"start\": [[13]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
18805724_1 | DISCUSSION: The main adverse effects of leflunomide consist of diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"effects\"]], \"start\": [[29]], \"entity_id\": [\"T15\"]}, \"Treatment\": {\"text\": [[\"leflunomide\"]], \"start\": [[40]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"leflunomide\"]], \"start\": [[40]], \"entity_id\": [\"T16\"]}}, \"Effect\": {\"text\": [[\"diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions\"]], \"start\": [[63]], \"entity_id\": [\"T14\"]}}"
}
]
}
] |
1445134_3 | In a single practice during the 21 years 1971-1991, the incidence of gestational diabetes in pregnancies in which norethisterone was prescribed was 32.4% (22 of 69) in comparison with 7.1% in pregnancies in which the women did not take norethisterone (137 of 1,684) (p < 0.001). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"incidence\"]], \"start\": [[56]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"gestational diabetes\"]], \"start\": [[69]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"pregnancies\"]], \"start\": [[93]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"norethisterone\"]], \"start\": [[114]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"norethisterone\"]], \"start\": [[114]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
1765991_2 | The development of systemic lupus erythematosus (SLE) after 38 months of therapy with recombinant human interferon gamma (rIFN-gamma) was observed in a patient with rheumatoid arthritis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[4]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"after 38 months\", \"recombinant human interferon gamma\"]], \"start\": [[54, 86]], \"entity_id\": [\"T11\"], \"Time_elapsed\": {\"text\": [[\"after 38 months\"]], \"start\": [[54]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"recombinant human interferon gamma\"]], \"start\": [[86]], \"entity_id\": [\"T15\"]}, \"Disorder\": {\"text\": [[\"rheumatoid arthritis.\"]], \"start\": [[165]], \"entity_id\": [\"T16\"]}}, \"Effect\": {\"text\": [[\"systemic lupus erythematosus\"]], \"start\": [[19]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"a patient with rheumatoid arthritis.\"]], \"start\": [[150]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
7668127_3 | To the best of our knowledge no comparable case and no discussion of possible complications of aspirin prophylaxis in patients with brain tumours have been published. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complications\"]], \"start\": [[78]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"patients with brain tumours\"]], \"start\": [[118]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"brain tumours\"]], \"start\": [[132]], \"entity_id\": [\"T11\"]}}, \"Treatment\": {\"text\": [[\"aspirin prophylaxis\"]], \"start\": [[95]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"aspirin\"]], \"start\": [[95]], \"entity_id\": [\"T12\"]}}, \"Negated\": {\"text\": [[\"no\"]], \"start\": [[52]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
16225183_6 | CASE REPORT: We present a case of a 28-yr-old male who developed a severe case of nephrotic syndrome while being treated for relapsing/remitting Multiple Sclerosis (RRMS) with weekly injections of interferon beta 1a. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[55]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"28-yr-old male\", \"relapsing/remitting Multiple Sclerosis (RRMS)\"]], \"start\": [[36, 125]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"28-yr-old\"]], \"start\": [[36]], \"entity_id\": [\"T14\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[46]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"nephrotic syndrome\"]], \"start\": [[82]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"weekly injections of interferon beta 1a\"]], \"start\": [[176]], \"entity_id\": [\"T11\"], \"Freq\": {\"text\": [[\"weekly\"]], \"start\": [[176]], \"entity_id\": [\"T16\"]}, \"Route\": {\"text\": [[\"injections\"]], \"start\": [[183]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"interferon beta 1a\"]], \"start\": [[197]], \"entity_id\": [\"T18\"]}, \"Disorder\": {\"text\": [[\"relapsing/remitting Multiple Sclerosis\"]], \"start\": [[125]], \"entity_id\": [\"T19\"]}}, \"Severity\": {\"text\": [[\"severe case\"]], \"start\": [[67]], \"entity_id\": [\"T13\"], \"value\": \"High\"}}"
}
]
}
] |
2369419_3 | This is the third report of reversible hepatic decompensation associated with prolonged MTX therapy in patients with rheumatoid arthritis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[62]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"reversible hepatic decompensation\"]], \"start\": [[28]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"MTX\"]], \"start\": [[88]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[117]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"MTX\"]], \"start\": [[88]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"patients with rheumatoid arthritis\"]], \"start\": [[103]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
17228132_6 | CONCLUSIONS: Acute severe hepatitis though rare is occasionally observed with EGFR inhibitors gefitinib or erlotinib. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"observed\"]], \"start\": [[64]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"EGFR inhibitors gefitinib or erlotinib\"]], \"start\": [[78]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"gefitinib\"], [\"erlotinib\"]], \"start\": [[94], [107]], \"entity_id\": [\"T10\", \"T11\"]}}, \"Effect\": {\"text\": [[\"Acute severe hepatitis\"]], \"start\": [[13]], \"entity_id\": [\"T8\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[19]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
24791374_6 | Propafenone is an established class IC antiarrhythmic drug commonly used in the treatment of atrial fibrillation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[80]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Propafenone\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"atrial fibrillation\"]], \"start\": [[93]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"Propafenone\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
9972383_3 | Reversible nonthrombocytopenic palpable purpura associated with metoclopramide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[48]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"metoclopramide\"]], \"start\": [[64]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"metoclopramide\"]], \"start\": [[64]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Reversible nonthrombocytopenic palpable purpura\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
2894766_2 | Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[129]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"sulfasalazine\", \"sulfasalazine\"]], \"start\": [[19, 115]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"sulfasalazine\"], [\"sulfasalazine\"]], \"start\": [[19], [115]], \"entity_id\": [\"T7\", \"T9\"]}, \"Disorder\": {\"text\": [[\"inflammatory bowel disease\"]], \"start\": [[56]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"lupus syndrome\"]], \"start\": [[137]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
6414095_1 | Transient hemiparesis caused by phenytoin toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Transient hemiparesis\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"phenytoin toxicity\"]], \"start\": [[32]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"phenytoin\"]], \"start\": [[32]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
2406680_2 | Sensorineural hearing loss due to quinine therapy for malaria has frequently been mentioned in the literature but has not been a subject of research during the last decades. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[27]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"quinine\"]], \"start\": [[34]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"malaria\"]], \"start\": [[54]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"quinine\"]], \"start\": [[34]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"Sensorineural hearing loss\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"frequently been mentioned\"]], \"start\": [[66]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
16527771_3 | We report a 78-year-old man who had acute unilateral total visual loss after retrogasserian phenol injection for the treatment of trigeminal neuralgia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[71]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"retrogasserian phenol injection\"]], \"start\": [[77]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"trigeminal neuralgia\"]], \"start\": [[130]], \"entity_id\": [\"T5\"]}, \"Route\": {\"text\": [[\"injection\"]], \"start\": [[99]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"phenol\"]], \"start\": [[92]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"a 78-year-old man\"]], \"start\": [[10]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"78-year-old\"]], \"start\": [[12]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[24]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"acute unilateral total visual loss\"]], \"start\": [[36]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
18983414_1 | Four months after receiving an orthotopic liver transplant, a 51-year-old man was admitted for progressive liver failure and severe hepatocellular necrosis thought to be due to tacrolimus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due to\"]], \"start\": [[170]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"tacrolimus\"]], \"start\": [[177]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"tacrolimus\"]], \"start\": [[177]], \"entity_id\": [\"T10\"]}, \"Time_elapsed\": {\"text\": [[\"Four months\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"progressive liver failure and severe hepatocellular necrosis\"]], \"start\": [[95]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"Four months after receiving an orthotopic liver transplant, a 51-year-old man\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"a 51-year-old\"]], \"start\": [[60]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.